Potter-dix Public Schools in Dix, NE - Clinic/Center

Potter-dix Public Schools is a primary clinic (Clinic/center - Public Health, State Or Local) in Dix, Nebraska. The current practice location for Potter-dix Public Schools is 304 Horrum St, Dix, Nebraska. For appointments, you can reach them via phone at (308) 682-5226. The mailing address for Potter-dix Public Schools is Po Box 149, Dix, Nebraska and phone number is (308) 682-5226.

Potter-dix Public Schools is licensed to practice in * (Not Available) (license number ) and its NPI number is 1205570744. This medical practice does not participate in medicare program and thus may not accept your medicare insurance. You may check if they accept your insurance at (308) 682-5226.

Contact Information

	Potter-dix Public Schools
	304 Horrum St Dix NE 69133-8960
	(308) 682-5226
	Not Available

Primary Care Clinic Profile

Full Name	Potter-dix Public Schools
Speciality	Clinic/center - Public Health, State Or Local
Location	304 Horrum St, Dix, Nebraska
Authorized Official Name and Position	Renae Monheiser (ADMINISTRATIVE ASSISTANT)
Authorized Official Contact	3086825226
Accepts Medicare Insurance	This clinic does not participate in Medicare Program.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Potter-dix Public Schools Po Box 149 Dix NE 69133-0149 Ph: (308) 682-5226	Potter-dix Public Schools 304 Horrum St Dix NE 69133-8960 Ph: (308) 682-5226

NPI Details:

NPI Number	1205570744
Provider Enumeration Date	04/21/2022
Last Update Date	04/21/2022

Medical Identifiers

Medical identifiers for Potter-dix Public Schools such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1205570744	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
261QP0905X	Clinic/center - Public Health, State Or Local	(* (Not Available))	Primary

News Archive

Gene therapy approach using CD59 shows promise against AMD: Study

A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration, according to a new in vivo study by researchers at Tufts University School of Medicine.

Christie introduces hand-held version of VeinViewer

Christie Medical Holdings, Inc. today announced the market launch of the company's newest product, VeinViewer Flex. With the addition of this fifth-generation VeinViewer, following the recent launch of VeinViewer VisionXTND, Christie now provides a full portfolio of three product tiers that addresses the needs of every major health care market segment.

Workplace barriers contribute to low rates of breastfeeding among mothers of new infants

For mothers of new infants, going back to work may pose a number of obstacles to continued breastfeeding. Workplace policies affecting the ability to breastfeed—and the role of nurse practitioners (NPs) in helping to overcome those obstacles—are the topic of a special article in The Nurse Practitioner, published by Wolters Kluwer.

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

BioNumerik Pharmaceuticals, Inc. today announced the treatment of the first patients in a global multi-center Phase III clinical trial of Tavocept (BNP7787) in patients with primary adenocarcinoma of the lung, the most common type of lung cancer. In previous studies, Tavocept demonstrated the potential to substantially increase overall and one year patient survival while concurrently preventing and reducing the incidence and severity of common chemotherapy side-effects as compared to other currently available treatments for advanced lung cancer.

Measuring gaze patterns of children watching movies can help detect autism

Measuring children's gaze patterns as they watch movies of social interactions is a reliable way to accurately identify nearly half of autism spectrum disorder cases, according to a new study just published in Autism Research by Ben-Gurion University of the Negev researchers.

Potter-dix Public Schools - Primary Care in Dix, NE